Know Cancer

or
forgot password

Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


Phase 2
49 Years
75 Years
Open (Enrolling)
Both
Myeloproliferative Disorders, Blood Cancer, Myelodysplastic Syndromes

Thank you

Trial Information

Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)


Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes
and Myeloproliferative Disorders (except CML). To evaluate the feasibility and safety of
TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid
conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.


Inclusion Criteria:



GENERAL INCLUSION CRITERIA

- General inclusion criteria must include at least one of the following:

- Patients aged > 49 and < 75 years with MDS or MPD

- Patients aged < 49 years at high risk for regimen related toxicity using
standard high dose regimens. Factors considered high risk include pre-existing
conditions such as a chronic disease affecting kidneys, liver, lungs, or heart.

- Patients with secondary MDS following a prior autologous transplant.

- An HLA-identical related or an HLA-matched unrelated donor is available. ABO
incompatibility is acceptable.

- A signed informed consent form.

MYELODYSPLASTIC SYNDROME CRITERIA

- Diagnosis of MDS classifiable by the FAB system as refractory anemia (RA), refractory
anemia with ringed sideroblasts (RARS), chronic myelomonocytic leukemia (CMML),
refractory anemia with excess blasts (RAEB), and MDS transformed to acute leukemia.

- Patients with advanced MDS must be cytoreduced to < 10% marrow blasts prior to
receiving conditioning with TLI/ATG. Less than 10% marrow blasts must be documented
by marrow examination within 1 month of starting conditioning. The cytoreductive
regimen will be determined by referring centers.

- Patients with evolution to AML are required to be in a complete remission as defined
by a blast count of less than 5% in a marrow aspirate with adequate cellularity.
Presence of residual dysplastic features following cytoreductive therapy is
acceptable.

- All patients with high risk disease, for example "intermediate-2" or "high risk"
disease by the IPSS score. Other selected patients with a lower IPSS score may be
considered but only after discussion with the BMT attending physicians, as a group,
and the PI of the study.

MYELOPROLIFERATIVE DISORDERS

- Myeloproliferative disorders to be included:

- Philadelphia chromosome-negative CML.

- Patients with polycythemia vera with persistent thrombotic or hemorrhagic
complications despite conventional therapy, or who have progressed to
post-polycythemic marrow fibrosis.

- Patients with essential thrombocythemia with persistent thrombotic or
hemorrhagic complications despite conventional therapy, or who have progressed
to myelofibrosis.

- Patients with agnogenic myeloid metaplasia with high risk disease, for example
"intermediate" or "high risk" according to the Lille Scoring System.

- Patients must be cytoreduced to < 10% marrow blasts. Less than 10% marrow blasts must
be documented by marrow examination within 1 month of initiation of TLI/ATG. The
cytoreductive regimen will be determined by referring centers.

- Patients with evolution to AML are required to be in a complete remission as defined
by a blast count of less than 5% in a marrow aspirate with adequate cellularity.
Presence of residual dysplastic features following cytoreductive therapy is
acceptable.

INCLUSION CRITERIA - RELATED DONORS

- Related to the patient and is genotypically or phenotypically HLA-identical.

- Donor age < 75 unless cleared by P.I

- Capable of giving written, informed consent.

- Donor must consent to PBSC mobilization with G-CSF and apheresis

INCLUSION CRITERIA - UNRELATED DONORS

- Donors must be HLA-matched as defined by the following criteria:

- Matched for HLA-DRB1 and DQB1 by high resolution typing.

- Serologic match for all recognized HLA-A, HLA-B, and HLA-C antigens, and
molecular match for at least 5 of 6 HLA-A, HLA-B, or HLA-C antigens by high
resolution typing.

- Donor must consent to PBSC mobilization with G-CSF and apheresis. Bone marrow
unrelated donors are not eligible for this protocol.

Exclusion Criteria:GENERAL EXCLUSION CRITERIA

- Organ dysfunction as defined by the following:

- Renal: Patients with a normal creatinine are eligible for study without the need
for a 24 hr urine collection for creatinine clearance. Patients with an elevated
creatinine require a 24 hr urine collection. If the creatinine clearance is < 50
ml/min patients will be determined for inclusion on a case by case basis.

- Cardiac: Ejection fraction < 40%, symptomatic congestive heart failure requiring
therapy, poorly controlled cardiac arrythmias, or poorly controlled hypertension
with inability to maintain a steady-state blood pressure of 150/90.

- Pulmonary: Requirement for supplemental oxygen administration, or pulmonary
function testing showing (1) DLCO < 50% of predicted, (2) TLC < 30%, or (3) FEV1
< 30%.

- Hepatic: Patients with clinical or laboratory evidence of liver disease would be
evaluated for the cause of liver disease, its clinical severity in terms of
liver function and degree of portal hypertension. Patients will be excluded if
they are found to have fulminant liver failure, cirrhosis if the liver with
evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a
history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable
hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time,
ascites related to portal hypertension, bacterial or fungal liver abscess.
Biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3
mg/dl, and symptomatic biliary disease.

- Bone marrow documenting blast count >=10%.

- Presence of active of non-hematologic malignancy (except localized non-melanoma skin
malignancies) or hematologic malignancy other than MDS or MPD as listed in inclusion
criteria.

- Active CNS involvement of disease.

- Karnofsky performance score <= 60% or Lansky-Play Performance score <50 for pediatric
patients.

- Life expectancy severely limited by diseases other than malignancy.

- Fungal infections with radiological progression despite with an amphotericin product
or active triazole for > 1 month.

- Active bacterial infection.

- Patients of fertile age who refuse contraception for a twelve month period
post-transplant.

- Pregnant or lactating females.

- HIV seropositivity.

- Severe psychological illness.

EXCLUSION CRITERIA - RELATED DONORS

- Identical twin

- Any contra-indication to the administration of subcutaneous G-CSF at a dose of
16mg/kg/d for five consecutive days

- Serious medical or psychological illness

- Pregnant or lactating females

- Prior malignancy within the preceding five years, with the exception of non-melanoma
skin cancers.

- HIV seropositivity

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To improve survival outcome for selected patients with advanced stages of MDS and MPD with non-myeloablative allogeneic HCT from related and unrelated donors.

Outcome Time Frame:

7/15/2017

Safety Issue:

No

Principal Investigator

Robert Lowsky

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT168

NCT ID:

NCT00185796

Start Date:

July 2004

Completion Date:

July 2017

Related Keywords:

  • Myeloproliferative Disorders
  • Blood Cancer
  • Myelodysplastic Syndromes
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Hematologic Neoplasms

Name

Location

Stanford University School of MedicineStanford, California  94305-5317